Revolutionizing Healthcare: Unveiling the Growth Trajectory of the Peptide Therapeutics Market

2 minutes, 56 seconds Read

The Peptide Therapeutics Market is poised for substantial growth, projected at a robust CAGR of around 9% during the forecast period. The surge is fueled by a confluence of factors, including the escalating incidence of cancer, intensified research and development endeavors for novel peptide therapeutics, and the burgeoning pipeline of innovative drugs. The global landscape is witnessing an alarming rise in chronic diseases, particularly diabetes and cardiovascular disorders, as highlighted by the World Health Organization (WHO), with chronic diseases accounting for 73 percent of all deaths and 60 percent of the global disease burden in 2020.

Access Sample PDF Here-

Driving Forces

Chronic Diseases: A Global Menace

Chronic diseases have become a global menace, infiltrating all regions and affecting diverse socioeconomic classes. The escalating rates, causing 73 percent of all deaths globally, have heightened the demand for efficacious therapeutics. This surge is anticipated to propel the peptide therapeutics market forward. Technological strides, such as the advent of peptide-based drugs, are contributing significantly to combatting chronic ailments.

Technological Advancements

The landscape is witnessing a paradigm shift with the development and introduction of innovative peptide therapeutics designed to tackle chronic diseases, particularly cancer. Noteworthy is the move by ISSAR Pharmaceuticals in May 2021, licensing its peptide-based new chemical entities (NCEs) with pre-IND filing, marking a significant leap in the quest for novel therapeutic solutions.

Major Market Players

In this dynamic landscape, major players like AbbVie Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Lilly, Sanofi, GSK plc, Novartis AG, and Takeda Pharmaceutical Company Limited are leading the charge. These industry giants are not only engaged in pioneering research and development but also strategically undertaking mergers and acquisitions, as well as partnerships, to usher in cutting-edge products and technologies.

Insights from the Report

Application Dynamics: Metabolic Segment Takes the Spotlight

The application segment reveals the metabolic segment as a major player in 2021, holding a significant market share. The rising geriatric population and the associated surge in metabolic disorders, exemplified by conditions like Gaucher disease (GD), are pivotal factors driving the growth of this segment. According to a July 2022 article in the journal JPHO, GD’s global prevalence was estimated at 0.9 cases per 100,000 inhabitants, underscoring the demand for peptide therapeutics in treating metabolic disorders.

Drug Type Evolution: Generic Category on the Rise

The market’s drug type classification into branded and generic drugs forecasts a significant rise in the generic category during the forecast period. With generic drugs priced 50%-65% lower than their branded counterparts, their adoption is on the upswing. This trend is further fueled by the expiration of patents for novel biologic drugs and substantial investments by pharmaceutical giants in generic drug development.

Distribution Channels: Hospital Pharmacies at the Helm

Hospital pharmacies emerged as dominant players in the distribution channel segment in 2021. Factors such as an increasing number of hospitalizations due to acute and chronic diseases, coupled with rising prescriptions, are propelling the demand for peptide therapeutics through hospital pharmacies.

Regional Powerhouse: APAC’s Ascendancy

The Asia-Pacific (APAC) region is poised for significant growth during the forecast period. This can be attributed to untapped opportunities, cost-effective raw materials, a thriving biotech industry, and escalating research and development activities. Notable collaborations, such as PeptiDream’s partnership with Eli Lilly in December 2022, further highlight the region’s commitment to advancing peptide-based drug discovery.

In conclusion, the Peptide Therapeutics Market stands at the forefront of revolutionizing healthcare. With a focus on addressing chronic diseases through innovative solutions, the market is not only witnessing substantial growth but also shaping the future of therapeutic interventions.

Similar Posts